Hile Bio-Technology shareholders approve major governance changes

Shanghai Hile Bio-Technology's first extraordinary general meeting of shareholders for 2025, held on October 9, 2025, approved several significant proposals. A total of 403 shareholders and proxies, representing 273,332,162 shares or 41.6879% of total voting shares, participated.

The most notable resolution, concerning the abolition of the supervisory board, changes to the registered address and business scope, and revisions to the company's articles of association, was passed with 272,060,578 A-shares voting in favor (99.5347%). This indicates a strong mandate for the proposed corporate restructuring. Shareholders also approved revisions to the "Shareholders' Meeting Rules of Procedure" and the "Rules of Procedure for the Board of Directors," with 270,047,191 A-shares (98.7981%) and 270,031,191 A-shares (98.7923%) in favor, respectively.

Other key resolutions included amendments to the "Independent Director Work System," "Related Party Transaction Implementation Rules," "Online Voting Rules for Shareholder Meetings," "Management System for Raised Funds," "External Guarantee Management System," and "External Investment Management System," all of which passed with substantial majority votes. Additionally, a proposal to adjust the transaction price for a major asset purchase and sign a supplementary agreement was approved by 272,033,832 A-shares (99.5249%).